CAMBRIDGE, Mass. , Nov. 18, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...

- Synlogic ends 3Q2020 with $102.0 million in cash, cash equivalents and investments supporting projected runway into 2022 -   - Phase 2 study of SYNB1618 and Phase 1 study of SYNB8802 initiated -   - Management to host conference call and webcast at 8:30 a.m. ET today - CAMBRIDGE, Mass. , Nov....

CAMBRIDGE, Mass. , Nov. 4, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced it has treated the first healthy volunteer in its Phase 1 study of the investigational Synthetic Biotic...

CAMBRIDGE, Mass. , Oct. 27, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2020 financial results before the market opens on Thursday,...

CAMBRIDGE, Mass. , Oct. 22, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present a poster on SYNB8802, an investigational Synthetic Biotic medicine for the treatment...

CAMBRIDGE, Mass. , Sept. 14, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of David Hava , Ph.D. as Chief Scientific Officer. Dr....

CAMBRIDGE, Mass. , Sept. 8, 2020 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's president and chief executive officer, and other members of...

- Synlogic ends 2Q2020 with $109.1 million in cash, cash equivalents and investments supporting projected runway into 2022 - Company continues to advance multiple clinical stage Synthetic Biotic medicines - Management to host conference call and webcast at 8:00 am ET today - CAMBRIDGE,...

CAMBRIDGE, Mass. , July 31, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's president and chief executive officer, and other members of...

CAMBRIDGE, Mass. , July 30, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Antoine 'Tony' Awad to the position of Chief Operating Officer....

CAMBRIDGE, Mass. , July 28, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2020 financial results before the market opens on Thursday,...

- SYNB1891 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma - CAMBRIDGE, Mass. , June 1, 2020 /PRNewswire/ --  Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel,...